Multifunctional Targeting Liposomes of Epirubicin Plus Resveratrol Improved Therapeutic Effect on Brain Gliomas

References

• Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392(10145):432–446.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017;19(suppl_5):v1–v88.
   PubMed Web of Science ®Google Scholar
• Ying X, Wen H, Lu W-L, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release. 2010;141(2):183–192.
   PubMed Web of Science ®Google Scholar
• Jia Y, Wang X, Hu D, et al. Phototheranostics: active targeting of orthotopic glioma using biomimetic proteolipid nanoparticles. ACS nano. 2019;13(1):386–398.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Gunn MD, Fecci PE, Ashley DM. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer. 2020;20(1):12–25.
   PubMed Web of Science ®Google Scholar
• Furtado D, Björnmalm M, Ayton S, Bush AI, Kempe K, Caruso F. Overcoming the blood-brain barrier: the role of nanomaterials in treating neurological diseases. Advan mater. 2018;30(46):e1801362.
   PubMed Web of Science ®Google Scholar
• Sarkaria JN, Hu LS, Parney IF, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 2018;20(2):184–191.
   PubMed Web of Science ®Google Scholar
• Sweeney MD, Ayyadurai S, Zlokovic BV. Pericytes of the neurovascular unit: key functions and signaling pathways. Nat Neurosci. 2016;19(6):771–783.
   PubMed Web of Science ®Google Scholar
• Xu -P-P, Fu D, Li J-Y, et al. Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, Phase 3, randomised, controlled trial. Lancet Haematol. 2019;6(6):e328–e337.
   PubMed Web of Science ®Google Scholar
• Perveen K, Masood F, Hameed A. Preparation, characterization and evaluation of antibacterial properties of epirubicin loaded PHB and PHBV nanoparticles. Int J Biol Macromol. 2020;144:259–266.
   PubMed Web of Science ®Google Scholar
• Pang -H-H, Chen P-Y, Wei K-C, et al. Convection-enhanced delivery of a virus-like nanotherapeutic agent with dual-modal imaging for besiegement and eradication of brain tumors. Theranostics. 2019;9(6):1752–1763.
   PubMed Web of Science ®Google Scholar
• Feijen EAM, Leisenring WM, Stratton KL, et al. Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity. JAMA Oncol. 2019;5(6):864–871.
   PubMed Web of Science ®Google Scholar
• Liu -J-J, Tang W, Fu M, et al. Development of R modified epirubicin-dihydroartemisinin liposomes for treatment of non-small-cell lung cancer. Artif Cells Nanomed Biotechnol. 2019;47(1):1947–1960.
   PubMed Web of Science ®Google Scholar
• van den Brand AD, Villevoye J, Nijmeijer SM, van den Berg M, van Duursen MBM. Anti-tumor properties of methoxylated analogues of resveratrol in malignant MCF-7 but not in non-tumorigenic MCF-10A mammary epithelial cell lines. Toxicology. 2019;422:35–43.
   PubMed Web of Science ®Google Scholar
• Yousef M, Vlachogiannis IA, Tsiani E. Effects of resveratrol against lung cancer: in vitro and in vivo studies. Nutrients. 2017;9:11.
   Web of Science ®Google Scholar
• Jeyaraman MM, Al-Yousif NSH, Singh Mann A, et al. Resveratrol for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020;1:CD011919.
   PubMedGoogle Scholar
• Mojarad-Jabali S, Farshbaf M, Walker PR, et al. An update on actively targeted liposomes in advanced drug delivery to glioma. Int J Pharm. 2021;602:120645.
   PubMed Web of Science ®Google Scholar
• Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative Western blotting and in situ hybridization. J Biol Chem. 1990;265(29):18035–18040.
   PubMed Web of Science ®Google Scholar
• McMullen E, Weiler A, Becker HM, Schirmeier S. Plasticity of carbohydrate transport at the blood-brain barrier. Front Behav Neurosci. 2020;14:612430.
   PubMed Web of Science ®Google Scholar
• Libbrecht S, Van den Haute C, Malinouskaya L, Gijsbers R, Baekelandt V. Evaluation of WGA-Cre-dependent topological transgene expression in the rodent brain. Brain Struct Funct. 2017;222(2):717–733.
   PubMed Web of Science ®Google Scholar
• Wang C, Ho PC, Lim LY. Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells. Int J Pharm. 2010;400(1–2):201–210.
   PubMed Web of Science ®Google Scholar
• Aires V, Colin DJ, Doreau A, et al. P-Glycoprotein 1 affects chemoactivities of resveratrol against human colorectal cancer cells. Nutrients. 2019;11:9.
   Web of Science ®Google Scholar
• Yang S, Jin H, Zhao Z. Paracellular tightness and the functional expression of efflux transporters P-gp and BCRP in bEnd3 cells. Neurol Res. 2018;40(8):644–649.
   PubMed Web of Science ®Google Scholar
• Li W, Ren L, Zheng X, et al. 3–Acetyl-11-keto- -boswellic acid ameliorated aberrant metabolic landscape and inhibited autophagy in glioblastoma. Acta pharmaceutica Sinica B. 2020;10(2):301–312.
   PubMed Web of Science ®Google Scholar
• Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016;15(4):275–292.
   PubMed Web of Science ®Google Scholar
• Tosi G, Duskey JT, Kreuter J. Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier. Expert Opin Drug Deliv. 2020;17(1):23–32.
   PubMed Web of Science ®Google Scholar
• Villaseñor R, Lampe J, Schwaninger M, Collin L. Intracellular transport and regulation of transcytosis across the blood-brain barrier. Cell Mol Life Sci. 2019;76(6):1081–1092.
   PubMed Web of Science ®Google Scholar
• Tang W, Fan W, Lau J, Deng L, Shen Z, Chen X. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. Chem Soc Rev. 2019;48(11):2967–3014.
   PubMed Web of Science ®Google Scholar
• Niu X, Chen J, Gao J. Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: focus on recent advances. Asian J Pharm Sci. 2019;14(5):480–496.
   PubMed Web of Science ®Google Scholar
• Francis GE, Delgado C, Fisher D, Malik F, Agrawal AK. Polyethylene glycol modification: relevance of improved methodology to tumour targeting. J Drug Target. 1996;3(5):321–340.
   PubMed Web of Science ®Google Scholar
• Shen Z, Ye H, Kröger M, Li Y. Aggregation of polyethylene glycol polymers suppresses receptor-mediated endocytosis of PEGylated liposomes. Nanoscale. 2018;10(9):4545–4560.
   PubMed Web of Science ®Google Scholar
• Mastrotto F, Brazzale C, Bellato F, et al. In vitro and in vivo behavior of liposomes decorated with PEGs with different chemical features. Mol Pharm. 2020;17(4):1444.
   PubMed Web of Science ®Google Scholar
• Steffes VM, Zhang Z, MacDonald S, et al. PEGylation of paclitaxel-loaded cationic liposomes drives steric stabilization of bicelles and vesicles thereby enhancing delivery and cytotoxicity to human cancer cells. ACS Appl Mater Interfaces. 2020;12(1):151–162.
   PubMed Web of Science ®Google Scholar
• Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99(Pt A):28–51.
   PubMed Web of Science ®Google Scholar
• Zhong L, Xu L, Liu Y, et al. Transformative hyaluronic acid-based active targeting supramolecular nanoplatform improves long circulation and enhances cellular uptake in cancer therapy. Acta pharmaceutica Sinica B. 2019;9(2):397–409.
   PubMed Web of Science ®Google Scholar
• Teleanu DM, Chircov C, Grumezescu AM, Volceanov A, Teleanu RI. Blood-brain delivery methods using nanotechnology. Pharmaceutics. 2018;10:4.
   Web of Science ®Google Scholar
• Zhu Q, Ling X, Yang Y, et al. Embryonic stem cells-derived exosomes endowed with targeting properties as chemotherapeutics delivery vehicles for glioblastoma therapy. Advan mater. 2019;6(6):1801899.
   Google Scholar
• Dallavalle S, Dobričić V, Lazzarato L, et al. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resist Updat. 2020;50:100682.
   PubMed Web of Science ®Google Scholar
• Maleklou N, Allameh A, Kazemi B. Targeted delivery of vitamin D3-loaded nanoparticles to C6 glioma cell line increased resistance to doxorubicin, epirubicin, and docetaxel in vitro. Vitro Cell Dev Biol Anim. 2016;52:10.
   PubMed Web of Science ®Google Scholar
• Han W, Shi J, Cao J, Dong B, Guan W. Emerging roles and therapeutic interventions of aerobic glycolysis in glioma. Onco Targets Ther. 2020;13:6937–6955.
   PubMed Web of Science ®Google Scholar
• Apfelthaler C, Skoll K, Ciola R, Gabor F, Wirth M. A doxorubicin loaded colloidal delivery system for the intravesical therapy of non-muscle invasive bladder cancer using wheat germ agglutinin as targeter. Eur J Pharm Biopharm. 2018;130:177–184.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Cheng L, Xie H-J, et al. Vinorelbine cationic liposomes modified with wheat germ agglutinin for inhibiting tumor metastasis in treatment of brain glioma. Artif Cells, Nanomed Biotechnol. 2018;46(sup3):):S524–S537.
   PubMed Web of Science ®Google Scholar
• Du D, Chang N, Sun S, et al. The role of glucose transporters in the distribution of p-aminophenyl-α-d-mannopyranoside modified liposomes within mice brain. J Control Release. 2014;182:99.
   PubMed Web of Science ®Google Scholar
• Liu L, Mu L-M, Yan Y, et al. The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer. Int J Nanomedicine. 2017;12:4163–4176.
   PubMed Web of Science ®Google Scholar
• Du J, Lu W-L, Ying X, et al. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol Pharm. 2009;6(3):905–917.
   PubMed Web of Science ®Google Scholar